Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease

Documents similaires

• Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
  par: Iskandar Idris
  Publié: (2024)
• Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
  par: Iskandar Idris
  Publié: (2024)
• Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
  par: Iskandar Idris
  Publié: (2024)
• Precision medicine approach to detect obese people who are at high risk of developing diabetes
  par: Iskandar Idris
  Publié: (2024)
• The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
  par: Iskandar Idris
  Publié: (2024)